NYSE:ZBH - Zimmer Biomet Stock Price, News & Analysis

$133.64
-3.47 (-2.53 %)
(As of 08/25/2019 10:22 AM ET)
Today's Range
$133.06
Now: $133.64
$137.28
50-Day Range
$117.52
MA: $130.36
$139.38
52-Week Range
$96.99
Now: $133.64
$140.53
Volume1.23 million shs
Average Volume1.50 million shs
Market Capitalization$27.44 billion
P/E Ratio17.49
Dividend Yield0.70%
Beta1.15
Zimmer Biomet Holdings, Inc, together with its subsidiaries, designs, manufactures, and markets musculoskeletal healthcare products and solutions in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. It operates through four segments: Spine, less Asia Pacific; Office Based Technologies; Craniomaxillofacial and Thoracic; and Dental. Read More…

Industry, Sector and Symbol

Industry Surgical appliances & supplies
Sub-IndustryN/A
SectorMedical
CUSIPN/A
Phone574-267-6131

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$7.93 billion
Cash Flow$17.1333 per share
Book Value$56.80 per share

Profitability

Net Income$-379,200,000.00

Miscellaneous

Employees19,000
Market Cap$27.44 billion
Next Earnings Date10/25/2019 (Estimated)
OptionableOptionable

Receive ZBH News and Ratings via Email

Sign-up to receive the latest news and ratings for ZBH and its competitors with MarketBeat's FREE daily newsletter.


Zimmer Biomet (NYSE:ZBH) Frequently Asked Questions

What is Zimmer Biomet's stock symbol?

Zimmer Biomet trades on the New York Stock Exchange (NYSE) under the ticker symbol "ZBH."

How often does Zimmer Biomet pay dividends? What is the dividend yield for Zimmer Biomet?

Zimmer Biomet declared a quarterly dividend on Tuesday, June 11th. Investors of record on Friday, June 28th will be paid a dividend of $0.24 per share on Wednesday, July 31st. This represents a $0.96 annualized dividend and a yield of 0.72%. The ex-dividend date of this dividend is Thursday, June 27th. View Zimmer Biomet's Dividend History.

How were Zimmer Biomet's earnings last quarter?

Zimmer Biomet Holdings Inc (NYSE:ZBH) posted its quarterly earnings results on Friday, July, 26th. The medical equipment provider reported $1.93 earnings per share (EPS) for the quarter, topping the Zacks' consensus estimate of $1.91 by $0.02. The medical equipment provider had revenue of $1.99 billion for the quarter, compared to analyst estimates of $1.98 billion. Zimmer Biomet had a negative net margin of 4.56% and a positive return on equity of 13.40%. Zimmer Biomet's revenue for the quarter was down .9% on a year-over-year basis. During the same period last year, the business earned $1.92 EPS. View Zimmer Biomet's Earnings History.

When is Zimmer Biomet's next earnings date?

Zimmer Biomet is scheduled to release their next quarterly earnings announcement on Friday, October 25th 2019. View Earnings Estimates for Zimmer Biomet.

What guidance has Zimmer Biomet issued on next quarter's earnings?

Zimmer Biomet issued an update on its FY19 earnings guidance on Friday, July, 26th. The company provided earnings per share (EPS) guidance of $7.75 -7.90 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $7.80. The company issued revenue guidance of $7.94 billion, compared to the consensus revenue estimate of prior $7.70-7.90.

What price target have analysts set for ZBH?

22 brokerages have issued 12 month target prices for Zimmer Biomet's shares. Their forecasts range from $108.00 to $167.00. On average, they expect Zimmer Biomet's share price to reach $141.5576 in the next year. This suggests a possible upside of 5.9% from the stock's current price. View Analyst Price Targets for Zimmer Biomet.

What is the consensus analysts' recommendation for Zimmer Biomet?

22 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Zimmer Biomet in the last year. There are currently 1 sell rating, 6 hold ratings, 14 buy ratings and 1 strong buy rating for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Zimmer Biomet.

What are Wall Street analysts saying about Zimmer Biomet stock?

Here are some recent quotes from research analysts about Zimmer Biomet stock:
  • 1. According to Zacks Investment Research, "We believe escalating costs and expenses are denting the adjusted operating margin for Zimmer Biomet. Adverse currency movements continue to be a concern. Declining dental sales at CER also disappoint. On a positive note, the company witnessed strength in the Asia Pacific and EMEA regions as well as in the Spine & CMF business. Supported by focus on priority areas like quality remediation, supply recovery efforts and product launches, the company has again reported strong top-line numbers for its S.E.T segment. We are also upbeat about the company’s receipt of FDA 510(k) for the ROSA Knee System. Zimmer Biomet has outperformed its industry in the past six months." (4/13/2019)
  • 2. BTIG Research analysts commented, "an easy comp led us to believe that 3Q results were beatable. While top-line fell in-line with the Street and EPS was 3 cents higher (which would have satisfied investors in our view), sentiment was hampered by commentary related to FY19 (specifically ongoing margin pressures and lost sales from ZBH’s distribution agreement with BONESUPPORT (BONEX-OM, Not Rated)). Underlying rev. growth of 2.0% Y/Y improved Y/Y (helped by 3Q tenders, ~40bps by our est.) and while GMs were soft (as expected in 3Q), mgmt. commentary indicates ongoing margin pressure into FY19 along with increasing Fx headwinds. Collectively headwinds will lower EPS by $0.15 in FY19, offset by a lower interest expense and tax rate." (10/28/2018)
  • 3. Needham & Company LLC analysts commented, "In an 8-K filed this morning, ZBH disclosed that it received a FDA warning letter late Friday, 8/24.The warning letter isn’t a surprise in our view given ZBH’s previous two Form 483s. While we think that the risk of a consent decree has probably increased, we still think it is very unlikely given ZBH’s significant efforts and investments in addressing the Biomet plant issues. We don’t expect any impact to ZBH’s financial results from the warning letter and maintain our Buy rating." (8/27/2018)
  • 4. Cantor Fitzgerald analysts commented, "We rate ZBH shares Overweight and have a 12-month price target of $150. ZBH has started a new era with recently hired the CEO of 10 years resigned in July. Under the new CEO near-term challenges persist, but we would expect the company to benefit from Hanson’s broader medtech background. ZBH is the least expensive large-cap medtech stock on a P/E basis, currently trading at a discount to the S&P. We believe the risk/reward is attractive at these levels and think there could be significant upside to shares if ZBH posts a couple of quarters of accelerating growth." (8/27/2018)

Has Zimmer Biomet been receiving favorable news coverage?

News headlines about ZBH stock have trended positive recently, InfoTrie Sentiment Analysis reports. InfoTrie rates the sentiment of press coverage by analyzing more than six thousand blog and news sources in real time. The firm ranks coverage of public companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Zimmer Biomet earned a news impact score of 2.5 on InfoTrie's scale. They also gave news headlines about the medical equipment provider a news buzz of 6.0 out of 10, indicating that recent press coverage is somewhat likely to have an effect on the company's share price in the next few days. View News Stories for Zimmer Biomet.

Who are some of Zimmer Biomet's key competitors?

What other stocks do shareholders of Zimmer Biomet own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Zimmer Biomet investors own include Celgene (CELG), AT&T (T), Cisco Systems (CSCO), General Electric (GE), Johnson & Johnson (JNJ), UnitedHealth Group (UNH), Visa (V), Bristol-Myers Squibb (BMY), CVS Health (CVS) and Citigroup (C).

Who are Zimmer Biomet's key executives?

Zimmer Biomet's management team includes the folowing people:
  • Mr. Bryan C. Hanson, Pres, CEO & Director (Age 52)
  • Mr. Daniel P. Florin Sr., Exec. VP & CFO (Age 55)
  • Mr. Chad F. Phipps, Sr. VP, Gen. Counsel & Sec. (Age 47)
  • Mr. Sang Yi, Pres of Asia Pacific (Age 57)
  • Mr. Ivan Tornos, Group Pres of Orthopedics (Age 43)

Who are Zimmer Biomet's major shareholders?

Zimmer Biomet's stock is owned by many different of institutional and retail investors. Top institutional investors include BlackRock Inc. (8.00%), BlackRock Inc. (8.00%), Vanguard Group Inc. (7.53%), JPMorgan Chase & Co. (4.78%), Invesco Ltd. (3.45%) and Price T Rowe Associates Inc. MD (2.95%). Company insiders that own Zimmer Biomet stock include Arthur J Higgins, Betsy J Bernard, Bryan C Hanson, Chad F Phipps, Katarzyna Mazur-Hofsaess, Michael J Farrell, Michael W Michelson, Sang Yi, Syed A Jafry and Tony W Collins. View Institutional Ownership Trends for Zimmer Biomet.

Which major investors are selling Zimmer Biomet stock?

ZBH stock was sold by a variety of institutional investors in the last quarter, including JPMorgan Chase & Co., Balyasny Asset Management LLC, First Trust Advisors LP, UBS Asset Management Americas Inc., Jennison Associates LLC, Jennison Associates LLC, Zurich Insurance Group Ltd FI and Bank of New York Mellon Corp. Company insiders that have sold Zimmer Biomet company stock in the last year include Chad F Phipps and Sang Yi. View Insider Buying and Selling for Zimmer Biomet.

Which major investors are buying Zimmer Biomet stock?

ZBH stock was acquired by a variety of institutional investors in the last quarter, including Nuveen Asset Management LLC, Invesco Ltd., Point72 Asset Management L.P., Prudential Financial Inc., Suvretta Capital Management LLC, Waddell & Reed Financial Inc., D. E. Shaw & Co. Inc. and Man Group plc. Company insiders that have bought Zimmer Biomet stock in the last two years include Arthur J Higgins, Betsy J Bernard, Bryan C Hanson, Michael J Farrell, Michael W Michelson and Syed A Jafry. View Insider Buying and Selling for Zimmer Biomet.

How do I buy shares of Zimmer Biomet?

Shares of ZBH can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Zimmer Biomet's stock price today?

One share of ZBH stock can currently be purchased for approximately $133.64.

How big of a company is Zimmer Biomet?

Zimmer Biomet has a market capitalization of $27.44 billion and generates $7.93 billion in revenue each year. The medical equipment provider earns $-379,200,000.00 in net income (profit) each year or $7.64 on an earnings per share basis. Zimmer Biomet employs 19,000 workers across the globe.View Additional Information About Zimmer Biomet.

What is Zimmer Biomet's official website?

The official website for Zimmer Biomet is http://www.zimmerbiomet.com/.

How can I contact Zimmer Biomet?

Zimmer Biomet's mailing address is 345 EAST MAIN STREET, WARSAW IN, 46580. The medical equipment provider can be reached via phone at 574-267-6131 or via email at [email protected]


MarketBeat Community Rating for Zimmer Biomet (NYSE ZBH)

Community Ranking:  2.7 out of 5 (star star)
Outperform Votes:  693 (Vote Outperform)
Underperform Votes:  587 (Vote Underperform)
Total Votes:  1,280
MarketBeat's community ratings are surveys of what our community members think about Zimmer Biomet and other stocks. Vote "Outperform" if you believe ZBH will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ZBH will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 8/25/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel